Endocrine Disorders Flashcards
ADA screening recommendations for dm
annual if bmi >25 and one/more risk factors for dm
every 3 yrs otherwise
prediabetes values
hga1c- 5.7-6.4%
FPG- 100-125
OGTT- 140-199
types ii dm values
hga1c- >6.5%
fpg- >126
ogtt- >200
random glucose with symptoms- >200
hga1c suggested goals
most adults- <7%
healthy older adults- <7.5%
physical exam monitoring for dm type ii
foot exam every 3 months
eye exam annually
recommendations for frequency of a1c testing in type ii dm
every 3 months if not at goal
otherwise every 6 months
biguanide example
metformin
sulfonylurea 2nd examples
glimepiride
glipzide
glyburide
meglitinides med example
repglinide
nateglinide
dpp-4 inhibit med examples
alogliptin
linagliptin
saxagliptin
sitagliptin
glp-1 med examples
exenatide
liraglutide
dulaglutide
semaglutide
tzd med examples
pioglitazone
rosiglitazone
sglt2 med examples
canaglifozin
dapaglifozin
empaglifozin
ertuglifolozin
sulfonylurea MOA and SE
potentiates insulin secretion
hypoglycemia, weight gain
dpp-4 moa and se
slows inactivation of incretin
“gliptins”, don’t use initially